Processa Pharmaceuticals Inc (nasdaq:PCSA) Share Price

Company Profile

Business description
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Contact
7380 Coca Cola Drive
Suite 106
HanoverMD21076
USA
T: +1 443 776-3133
https://www.processapharmaceuticals.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
13

Recommended

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.

Susan Dziubinski | 30 July 2025

We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.

Shaun Ler | 30 July 2025

With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.

Malik Ahmed Khan, CFA | 30 July 2025

Index	Last price	Change	% Change
All Ordinaries	9,003.50	11.90	-0.13%
CAC 40	7,861.96	4.60	0.06%
DAX 40	24,262.22	44.85	0.19%
Dow JONES (US)	44,461.28	171.71	-0.38%
FTSE 100	9,136.94	0.62	0.01%
HKSE	24,906.39	270.54	-1.07%
NASDAQ	21,129.67	31.38	0.15%
Nikkei 225	41,020.79	366.09	0.90%
NZX 50 Index	12,836.39	19.58	-0.15%
S&P 500	6,362.90	7.96	-0.12%
S&P/ASX 200	8,749.30	7.10	-0.08%
SSE Composite Index	3,591.26	24.46	-0.68%